Belite Bio (NASDAQ:BLTE) Price Target Raised to $200.00 at HC Wainwright

Belite Bio (NASDAQ:BLTE) had its price target boosted by HC Wainwright from $185.00 to $200.00 in a research report sent to investors on Tuesday morning,Benzinga reports. They currently have a buy rating on the stock.

A number of other research analysts also recently weighed in on BLTE. Cantor Fitzgerald raised their price objective on Belite Bio from $200.00 to $266.00 and gave the company an “overweight” rating in a research note on Tuesday. Wall Street Zen lowered shares of Belite Bio from a “hold” rating to a “sell” rating in a research report on Sunday, January 4th. Benchmark restated a “buy” rating on shares of Belite Bio in a research note on Tuesday. Maxim Group set a $200.00 target price on shares of Belite Bio in a research note on Tuesday, December 2nd. Finally, Bank of America assumed coverage on shares of Belite Bio in a report on Monday, January 26th. They issued a “buy” rating and a $195.00 target price on the stock. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $202.33.

Belite Bio Trading Down 5.5%

Belite Bio stock opened at $167.88 on Tuesday. Belite Bio has a 1-year low of $49.00 and a 1-year high of $200.00. The firm’s fifty day simple moving average is $168.93 and its 200-day simple moving average is $123.30. The company has a market capitalization of $6.30 billion, a P/E ratio of -72.99 and a beta of -1.46.

Belite Bio (NASDAQ:BLTE) last posted its earnings results on Monday, March 2nd. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.18. On average, equities research analysts predict that Belite Bio will post -1.17 earnings per share for the current year.

Institutional Investors Weigh In On Belite Bio

Several hedge funds and other institutional investors have recently modified their holdings of BLTE. Caitong International Asset Management Co. Ltd increased its position in Belite Bio by 28,200.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 283 shares of the company’s stock worth $45,000 after acquiring an additional 282 shares during the period. Bank of America Corp DE increased its holdings in shares of Belite Bio by 28.1% during the 3rd quarter. Bank of America Corp DE now owns 1,171 shares of the company’s stock worth $87,000 after purchasing an additional 257 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Belite Bio during the 4th quarter worth about $103,000. Persistent Asset Partners Ltd acquired a new position in shares of Belite Bio during the fourth quarter valued at about $108,000. Finally, GAMMA Investing LLC lifted its stake in shares of Belite Bio by 11.1% in the third quarter. GAMMA Investing LLC now owns 1,758 shares of the company’s stock valued at $130,000 after buying an additional 176 shares during the period. Institutional investors and hedge funds own 0.53% of the company’s stock.

More Belite Bio News

Here are the key news stories impacting Belite Bio this week:

• Positive Sentiment: Multiple brokerages raised targets and ratings — Cantor Fitzgerald to $266 (overweight), Morgan Stanley to $201 (overweight), and HC Wainwright to $200 (buy), implying high upside from current levels and reflecting bullish analyst conviction. Analyst Price Target Raises
• Positive Sentiment: Belite reported a Q4 beat: EPS of ($0.38) vs. consensus ($0.56), which reduces near-term execution risk and supports valuation upgrades. Earnings Results & Call
• Positive Sentiment: Company update targets a Q2 2026 NDA submission for its Stargardt program and plans $200M–$250M commercialization spend; management also reports rising cash reserves — this is a material development for future revenue potential and commercialization planning. NDA Timeline & Commercialization Plan
• Neutral Sentiment: Belite will participate in investor conferences (Leerink Global Healthcare), and transcripts/slides from the earnings call are available — helpful for due diligence but not immediate stock-moving by themselves. Conference Participation
• Neutral Sentiment: Multiple earnings-call transcripts and the company’s preliminary Q4/full-year press release and slide deck were published — useful context for analysts and investors. Press Release & Slides
• Neutral Sentiment: Short-interest entries published appear inconsistent (reports show “0 shares” and NaN changes, days-to-cover 0.0) — the data looks erroneous, creating unclear signal regarding bearish positioning. Investors should watch reliable short-interest filings for any true build in shorts.
• Negative Sentiment: Despite the positive fundamental and analyst news, the stock is down today — likely reflection of profit-taking after a recent run toward the 1-year high, or broader market/sector weakness; this intraday decline may be temporary unless follow-through negative news appears.

Belite Bio Company Profile

Belite Bio, Inc (NASDAQ: BLTE) is a clinical-stage biotechnology company focused on discovering and developing small molecule therapeutics for metabolic and inflammatory diseases. Leveraging a proprietary drug-discovery platform, the company aims to address conditions such as nonalcoholic steatohepatitis (NASH) and obesity by targeting pathways involved in fibrosis, inflammation and metabolic regulation.

Belite Bio’s pipeline includes multiple candidates in preclinical and early clinical development stages.